We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.50 | 26.00 | 29.00 | 27.50 | 27.50 | 27.50 | 29,393 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
1 October 2024
Argent BioPharma Ltd.
(Argent BioPharma or the Company)
Results of Shareholder's General Meeting
Argent BioPharma is pleased to announce the voting results from the Company's General Meeting of Shareholders held today, Tuesday, 1 October 2024.
The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.
Details of the results can be found in the following URL:
https://www.investi.com.au/api/announcements/rgt/4ae25edd-f7d.pdf
Additionally, the Company advises that it is actively progressing towards the appointment of a sponsor, a key step in moving its listing category from Equity Shares (International Commercial Companies - Secondary Listing) to Equity Shares (Commercial Companies) category (ESCC) of the FCA's Official List. Following the appointment of a sponsor, the Company will be in a position to submit an application to the Financial Conduct Authority (FCA) to facilitate the move between listing categories. Once this process is complete, the Company will provide an updated indicative timetable outlining the anticipated ASX delisting timeline, in accordance with the approval granted by shareholders at the General Meeting held today.
There can be no guarantee whether or when an Application to transfer listing category will be approved, notwithstanding the shareholder approval granted today. The Company will not delist from the ASX without such approval of the Application to transfer to the ESCC.
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950
|
Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 |
About Argent BioPharma
Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions